Medical Oncology

Doç. Dr. Eda Tanrıkulu Şimşek

Doctor and researcher Anadolu Sağlık Merkezi Hastanesi Kocaeli

Medical Oncology. The branch of medicine that looks after cancers, illnesses in which cells of the body multiply out of control and form tumours.

Open institution page
Suggest a correction

Is this your profile? Claim it and verify your details.

Claim profile

Person ↔ Disease

Which topics does this doctor work on?

From source

Medical areas of interest the doctor lists on their own profile on the institution’s website. Source: anadolusaglik.org.

  • Onkoloji Merkezi (Kanser Merkezi)
  • Kemoterapi
  • Meme kanseri
  • Ürolojik kanserler
  • Akciğer kanseri
  • Kolon ve rektum kanserleri
  • Mide kanseri
  • Pankreas kanseri
  • Özofagus kanseri
  • Jinekolojik kanserler
  • Malign melanom
  • Yumuşak doku sarkomları ve kemik tümörleri
  • Kişiye özgü bireyselleştirilmiş tedaviler
  • Immunoterapi ve hedefe yönelik tedaviler

CV

Education and experience

From source

2021 yılından bu yana Anadolu Sağlık Merkezi’nde tıbbi onkoloji uzmanı olarak görevini sürdürüyor.

Experience

  • Experienceİstanbul Üniversitesi Cerrahpaşa Tıp Fakültesianadolusaglik.org
  • ExperienceMarmara Üniversitesi Tıp Fakültesianadolusaglik.org
  • ExperienceŞanlıurfa Mehmet Akif İnan Eğitim ve Araştırma Hastanesianadolusaglik.org
  • ExperienceHaydarpaşa Numune Eğitim ve Araştırma Hastanesianadolusaglik.org
  • ExperienceAnadolu Sağlık Merkezianadolusaglik.org

Education

  • Education2005 - Ankara Üniversitesi Tıp Fakültesi, Tıp Doktoru, Ankaraanadolusaglik.org
  • Education2012 - İstanbul Üniversitesi, Cerrahpaşa Tıp Fakültesi, İç Hastalıkları Uzmanı,İstanbulanadolusaglik.org
  • Education2017 - Marmara Üniversitesi, Tıp Fakültesi, Medikal Onkoloji Uzmanı, İstanbulanadolusaglik.org

Trust

Where does this information come from?

The source is stated next to each piece of information. If you see something wrong, you can suggest a correction.

  • SpecialtyMedical Oncologyanadolusaglik.orgFrom source
  • Department name in the sourceMedikal Onkolojianadolusaglik.orgFrom source
  • InstitutionAnadolu Sağlık Merkezi Hastanesianadolusaglik.orgFrom source
  • Publications30 publicationsanadolusaglik.org profile pageFrom source
  • Last synchronised11 November 2026 22:58https://www.anadolusaglik.org/doktor/eda-tanrikulu-simsekanadolusaglik.org

Scientific work

Publications

30 publications

  1. Simsek ET, Coban E, Atag E, Gungor S, Sari M, Gurleyik G. The Role of FDG PET/CT to Evaluation of Axillary Lymph Nodes after Neoadjuvant Chemotherapy in Breast Cancer. J Coll Physicians Surg Pak. 2021 Jul;30(7):792-797.

    Source: anadolusaglik.org profile page

  2. Tanrikulu Simsek E, Eskazan AE, Cengiz M, Ar MC, Ekizoglu S, Salihoglu A, Gulturk E, Elverdi T, Ongoren Aydin S, Senem Demiroz A, Buyru AN, Baslar Z, Ozbek U, Ferhanoglu B, Aydin Y, Tuzuner N, Soysal T. Imatinib reduces bone marrow fibrosis and overwhelms the adverse prognostic impact of reticulin formation in patients with chronic myeloid leukaemia. J Clin Pathol. 2016 Sep;69(9):810-6.

    Source: anadolusaglik.org profile page

  3. Tanrikulu Simsek E, Dane F. Nutrition in Cancer Patients Who Have Problems in Oral Taking. Türkiye Klinikleri Tıbbi Onkoloji Kanser ve Beslenme Özel sayısı. Turkiye Klinikleri J Med Oncol-Special Topics. 2016;9(3):58-64.

    Source: anadolusaglik.org profile page

  4. Tanrikulu Simsek E, Dane F. Primary Central Nervous System Lymphomas: Diagnosis, Staging and Systemic Treatment. Erişkin Santral Sinir Sistemi Tümörleri Özel sayısı. Turkiye Klinikleri J Med Oncol-Special Topics. 2019. p.78-83.

    Source: anadolusaglik.org profile page

  5. Tanrıkulu Şimşek E, Beşiroglu M, Aktaş B, Koca S, Halil S, Alan Ö, Hasanov R, Akgül Babacan N, Öztürk MA, Kaya S, Ozdogan OC, Dane F, Yumuk PF. Can we Restart Vemurafenib after Severe Hepatotoxicity? A Case Report. J J Gastro Hepato. 2015, 2(4): 025.

    Source: anadolusaglik.org profile page

  6. Simsek ET, Coban E, Atag E, Gungor S, Aker F, Sari M. The Effect of FDG-PET/CT on Clinical Prognostic Staging of Breast Cancer Patients Planning Neoadjuvant Treatment. J Coll Physicians Surg Pak. 2021

    Source: anadolusaglik.org profile page

  7. Tanrıkulu Şimşek E, Bayram B, Yıldırım A, Eşkazan AE. Is it possible to predict the pCR with CBC? A commentary on "correlation analysis of lymphocyte-monocyte ratio with pathological complete response and clinical prognosis of neoadjuvant chemotherapy in patients with breast cancer" by Meng et al. Transl Oncol. 2022 Jun;20:101403. doi: 10.1016/j.tranon.2022.101403. Epub 2022 Mar 23.

    Source: anadolusaglik.org profile page

  8. Alan O, Akin Telli T, Ercelep O, Tanrikulu Simsek E, Basoglu Tuylu T, Mutis A, Hasanov R, Kaya S, Akgül Babacan N, Dane F, Yumuk PF. Chordoma: a case series and review of the literature. J Med Case Rep. 2018 Aug 27;12(1):239.

    Source: anadolusaglik.org profile page

  9. Alan O, Telli TA, Ercelep O, Hasanov R, Simsek ET, Mutis A, Ones T, Kaya H, Yumuk PF. A case of primary squamous cell carcinoma of the breast with pathologic complete response after neoadjuvant chemotherapy. Curr Probl Cancer. 2019 Aug;43(4):308-311

    Source: anadolusaglik.org profile page

  10. Kaya S, Aktas B, Tanrikulu Simşek E, Akif Ozturk M, Dede F, Kaya H, Ugurlu U, Ozgen Z, Koca S, Halil S, Hasanov R, Alan O, Akgul Babacan N, Ercelep O, Dane F, Gumus M, Yumuk F. Changes in 18F-FDG-PET/CT tumor metabolism are not consistent with pathologic complete response in hormone-positive breast cancer. J BUON. 2017 Sep-Oct;22(5):1191-1198.

    Source: anadolusaglik.org profile page

View all 30 publications